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Intracellular hyaline bodyteristic morphological features of various neuronal, muscular and other human
disorders. They share common molecular constituents such as p62, chaperones and proteasome subunits.
The proteins within aggregates are misfolded with increased β-sheet structure, they are heavily
phosphorylated, ubiquitinylated and partially degraded. Furthermore, involvement of proteasomal system
represents a common feature of virtually all inclusions. Multiple aggregates contain intermediate ﬁlament
proteins as their major constituents. Among them, Mallory–Denk bodies (MDBs) are the best studied. MDBs
represent hepatic inclusions observed in diverse chronic liver diseases such as alcoholic and non-alcoholic
steatohepatitis, chronic cholestasis, metabolic disorders and hepatocellular neoplasms. MDBs are induced in
mice fed griseofulvin or 3,5-diethoxycarbonyl-1,4-dihydrocollidine and resolve after discontinuation of toxin
administration. The availability of a drug-induced model makes MDBs a unique tool for studying inclusion
formation. Our review summarizes the recent advances gained from this model and shows how they relate to
observations in other aggregates. The MDB formation-underlying mechanisms include protein misfolding,
chaperone alterations, disproportional protein expression with keratin 8Nkeratin 18 levels and subsequent
keratin 8 crosslinking via transglutaminase. p62 presence is crucial for MDB formation. Proteasome inhibitors
precipitate MDB formation, whereas stimulation of autophagy with rapamycin attenuates their formation.
© 2008 Elsevier B.V. All rights reserved.1. Mallory–Denk bodies represent a unique tool to investigate
aggregate pathogenesis
Intracellular protein aggregates such as neuroﬁbrillary tangles
(Alzheimer's disease), Lewy bodies (Parkinson disease) or Mallory–
Denk bodies (various chronic liver diseases) are morphological
features of a variety of neurodegenerative, muscular and other
diseases [1–3]. Inclusion bodies typically consist of misfolded and
ubiquitinylated structural proteins together with variable amounts of
chaperones and the ubiquitin-binding protein sequestosome 1/p62
(p62; [4–6]). Based on the type of predominant structural protein,
aggregates can be divided into subgroups such as synucleinopathies,
tauopathies, polyglutamine- or intermediate ﬁlament-containing
inclusions or TDP-43 (TAR-DNA binding protein 43) proteinopathies
(Table 1). Aggregates share several features such as the presence of
highly insoluble, hyperphosphorylated and often crosslinked proteins
which suggest common principles underlying their pathogenesis.
Furthermore, aggregated proteins are often overexpressed or present
at altered stoichiometric ratios.
While considerable efforts focused on elucidating the pathogenesis
of tau- and synuclein-related disease processes, the formation and+43 316 384329.
nk).
ll rights reserved.signiﬁcance of intermediate ﬁlament (IF)-related aggregates is less
well understood. The goal of our present review is to summarize the
present knowledge about prototypic IF-related aggregates termed
Mallory–Denk-bodies (MDBs; [7]), and to highlight how the under-
standing of hepatic inclusion body formation may enhance our
perception of aggregates seen in neurodegenerative and other
disorders. A special emphasis will be placed on the ubiquitin–
proteasome system (UPS),which represents one of themost consistent
players in the development of aggregates.
IFs are components of the cytoskeleton and involved, in coopera-
tion with actin microﬁlaments and the microtubules, in the main-
tenance of cell shape, locomotion, intracellular organization and
transport [8,9]. IF proteins are encoded by ∼70 different genes and
comprise six subtypes which are, at least in part, expressed in a cell
type (and differentiation)-dependent manner [10–12]. The family of
IFs comprises type I (acidic) and type II (basic) keratins, type III
vimentin, desmin, glial ﬁbrillary acidic protein, peripherin, and
syncoilin, type IV neuroﬁlaments, α-internexin, nestin and synemin,
type V nuclear lamins, forming a meshwork at the inner layer of the
nuclear membrane, and the “orphan” cytoskeletal proteins phakinin
and ﬁlensin [10,12]. IFs are rather insoluble protein structures which
are the major constituents of protein aggregates found in several
hepatic, neurodegenerative and muscular disorders (Table 1;
[1,10,13]). In addition, IFs represent regular components of structures
called aggresomes, which arise when multiple small aggregates are
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dependent manner [14].
MDBs are the most prevalent and the best understood IF-related
aggregates. They are hallmarks of steatohepatitis of the alcoholic
(ASH) and non-alcoholic type (NASH; Fig. 1). They are also seen in a
variety of other chronic liver disorders including chronic cholestasis,
particularly late stages of primary biliary cirrhosis (Fig. 1c), Wilson
disease and other copper-related disorders, various metabolic dis-
turbances and hepatocellular neoplasms [7,15]. In idiopathic copper
toxicosis and hepatocellular carcinoma (HCC), MDBs may concur with
another type of cytoplasmic inclusions, termed intracellular hyaline
bodies (IHBs), which share several components, except keratins, with
MDBs (Fig. 2; [7,16]). For example, about 16% of HCCs contain IHBs only
and additional 16% contain both IHBs and MDBs, sometimes within
the same cell suggesting a close relationship. Both types of inclusions
share ﬁlamentous ultrastructure and IHBs have been designated as
“globular” and MDBs as “reticular” hyaline [17]. In human diseases,
“hybrid” inclusions were observed exhibiting a combination of
morphologic and immunohistochemical features of both types of
inclusions: IHB-like inclusions containing a small amount of (usually
granular) keratin, and conversely, MDB-like aggregates with less
densely arranged keratin granules (Fig. 2). On the basis of in vitro
transfection studies, the following scenarios leading to formation of
MDBs, IHBs, and hybrids was proposed [18]: (i) classical MDBs arise if
p62 and abnormal keratins accumulate at the same time in the cell in
comparable amounts (Fig. 3); (ii) hybrid inclusions are formed when
p62 amounts exceed the levels of aggregation-prone keratins, and (iii)
IHBs result if only p62 is overexpressed without sufﬁcient amounts of
abnormal keratins. It is currently unknown, whether IHBs represent
“pure” p62 aggregates or whether they contain additional, yet
unidentiﬁed proteins.
MDBs can be easily reproduced in a mouse model by chronic
griseofulvin or 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) feed-
ing [7,19]. MDB formation in mice and humans is reversible in that
they become smaller and less numerous after discontinuation of the
causative agent [7,20]. However, both “recovered” humans and
animals remain highly predisposed to MDB re-formation [7,15].
Moreover, the MDB re-appearance can be induced by a variety of
rather non-speciﬁc stress inducing agents as it has been shown inTable 1
Examples of intracellular protein aggregates (inclusions) and corresponding human disease
Subgroupa Inclusion body Major protein constituent U
IF-related inclusions Mallory–Denk body K8/K18 +
Desmin bodies Desmin +
NF inclusions NF +
Rosenthal ﬁbers GFAP, vimentin +
Tauopathies Neuroﬁbrillary tangles Tau +
Neuroﬁbrillary tangles Tau +
Pick body Tau +
Synucleinopathies Lewy bodies α-Synuclein +
GCI α-Synuclein +
Lewy bodies α-Synuclein +
Polyglutamine diseases Huntingtin +
Atrophin-1 +
Ataxin-1 +
TDP-43 proteinopathies TDP-43 +
TDP-43 +
Others – APP, Tau, others +
IHB p62 +
IHB p62 +
Bunina bodies SOD 1 +
ALS, amyotrophic lateral sclerosis; APP, Amyloid-β precursor protein; ASH, alcoholic steato
degeneration with ubiquitin positive, tau-/α-synuclein negative inclusions; GCI, glial
steatohepatitis; N.D., not determined; NF, neuroﬁlament; NIFID, neuronal ﬁlament inclusio
hepatocellular carcinoma; ICT, idiopathic copper toxicosis; SOD 1, superoxide dismutase 1;
a The classiﬁcation into groups is based on the predominant aggregate constituents. Fo
quantities of neuroﬁlaments, i.e. members of IF protein family [1].mice recovered on standard diet for one month, which are therefore
termed as “primed mice” [7].
Despite the existence of several cell culture-based models [7,18],
mouse studies were pivotal in elucidating the pathogenesis of MDB
formation [7,21]. In themousemodel of MDB formation aggregates are
induced by feeding a toxic substance. This is reminiscent of Parkinson
disease models, where intravenously or subcutaneously administered
drugs lead to generation of proteinacous deposits [22]. In contrast,
most animal models rely on genetic methods such as overexpression
of wild-type protein or introduction of mutant proteins [13,23,24].
This approach is well suited to mimic genetically simple human
diseases (such as diseases caused by expanded polyglutamine
repeats), however the most common human inclusion bodies are
found in genetically complex disorders such as Parkinson or
Alzheimer's disease (Table 2) [24]. The availability of a drug-induced
model of human inclusion body formation represents an interesting
alternative to study the pathogenesis and biological signiﬁcance of
such aggregates. Furthermore, a non-genetic model allows a con-
venient testing of factors potentially involved in inclusion formation,
since there is no need for generating multiple transgenic animals.
Hepatic aggregates are also ideally suited for pharmaceutical trials due
to the ease of drug delivery and tissue availability. The goal of our
review is to summarize the recent advances gained from the MDB
mouse model and to show how they can enhance our understanding
of aggregates seen in multiple other diseases. As a part of the theme
edition, our review will put a special emphasis on UPS.
2. Inclusion bodies share common molecular constituents
While earlier studies suggested that inclusion bodies consist of
randomly trapped proteins, it is now believed that they represent
highly organized structures of proteins involved in their pathogenesis
[25]. As a reﬂection of common underlying mechanisms, aggregates
share several common constituents such as chaperones, ubiquitin,
UBB(+1), p62, Valosin-containing protein, NEDD8 or proteasome
subunits. Chaperones are among the most prominent components of
inclusion bodies which likely try to refold damaged proteins or to
wrap them up to limit toxic interactions with other cellular
components [5,6]. Although chaperones are rather constant featuress
biquitin P62 Cell type Disease
+ Hepatocyte ASH, NASH, etc
+ Myocytes Desminopathies
/− N.D. Neurons NIFID
+ Astrocyte Alexander's disease etc
+ Neurons Alzheimer's disease
+ Neurons PSP
+ Neurons Pick's disease
/− + Neurons Parkinson disease
/− + Oligodendrocytes Multiple system atrophy
/− + Neurons Dementia with Lewy bodies
+ Neurons Huntington's disease
N.D. Neurons DRPLA
N.D. Neurons Spinocerebellar ataxia 1
+/− Neurons, oligodendrocytes FTLD-U
+ Neurons ALS
N.D. Myocytes Inclusion body myositis
/− + Tumor cells HCC
/− + Hepatocytes ICT
+ Neurons Familiar ALS
hepatitis; DRPLA, Dentatorubral pallidoluysian atrophy; FTLD-U, Frontotemporal lobar
cytoplasmic inclusions; IF, intermediate ﬁlament; K, keratin; NASH, non-alcoholic
n disease; PSP, Progressive supranuclear palsy; IHB, intracellular hyaline bodies; HCC,
TDP-43, TAR-DNA binding protein 43.
r example, Lewy bodies belong to synucleinopathies even though they contain minor
Fig. 1. Histological and ultrastructural features of alcoholic and non-alcoholic steatohepatitis. (a, b) Alcoholic steatohepatitis is characterized by steatosis, ballooning of hepatocytes,
MDB formation (arrows in a, b), neutrophil-granulocytic inﬂammation as well as pericellular ﬁbrosis. (c) At the ultrastructural level, MDBs consist of irregularly arranged ﬁlamentous
rods (type II according to Yokoo, upper panel) and sometimes contain an electron-dense granular core highlighted by asterisk (type III according to Yokoo, lower panel). (d–f)
Ballooning degeneration of hepatocytes, often associatedwith pericellular ﬁbrosis (arrowheads in f), andMDB appearance is also seen in non-alcoholic steatohepatitis (arrows in d, e).
(g, h) In idiopathic copper toxicosis, ballooned MDB-containing hepatocytes are often surrounded and even penetrated by neutrophils (arrow in g). Furthermore, intracellular hyaline
bodies (IHBs) may be present evenwithin the same cell and in close association with MDBs (arrows in h); (a,d,e,g,h), hematoxylin and eosin staining; (b, f), chromotrope aniline blue
staining.
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deposits. For example, MDBs contain signiﬁcant amounts of heat
shock proteins (Hsp) 70 and 90, whereas Hsp27 and αB-crystallin,
which are the major chaperones seen in Rosenthal ﬁbers, are not
obligatory constituents of MDBs [4,13,26]. In Lewy bodies, crystallins
and Hsp90, but not Hsp70 belong to the main components [27].
Although the precise reason for such heterogeneity is unknown, thedifferent structural components of inclusion bodies might be
responsible. For example, keratins (i.e. the major constituents of
MDBs, Fig. 3a,b,d) associate with Hsp70 [28], whereas glial ﬁbrillary
acidic protein (GFAP), which is part of Rosenthal ﬁbers, preferentially
binds Hsp27 and αB-crystallin [29].
Valosin-containing protein (VCP/p97) has been observed in multi-
ple aggregates including MDBs [30,31]. VCP/p97 belongs to the AAA
767P. Strnad et al. / Biochimica et Biophysica Acta 1782 (2008) 764–774class of ATPases and seems to be involved both in protein aggregate
formation and clearance [31,32]. In the case of MDBs, reduction of
VCP/p97 increases inclusion body formation, whereas overexpression
did not have an obvious effect [30]. In a cell culture model of
polyglutamine diseases, VCP/p97 decrease delays aggregate clearance
[31]. In humans, a mutation in VCP/p97 causes inclusion body
myopathy associated with Paget disease of bone and frontotemporal
dementia [33].
Several shared inclusion body constituents are involved in protein
degradation. Most aggregates consist of highly ubiquitinylated
proteins, which likely reﬂect the cellular attempt to target misfoldedFig. 2. IHBs and MDBs are observed in hepatocellular carcinoma and idiopathic copper tox
toxicosis (c–g) were visualized with chromotrope aniline blue staining (a) or immunohistoche
well as IHBs react with ubiquitin (e) and p62 (b, f, g) antibodies (IHBs are indicated by arrow
(arrowheads in c, d), whereas IHBs are typically keratin-negative (arrows in c, d). However, so
a matrix for incorporation of keratins. Note that hepatocytes within the presented idiopath
whereas the presented trabecular hepatocellular carcinoma harbours only IHBs.proteins for proteasomal degradation. However, dependent on the
particular lysine involved, protein ubiquitinylation may also facilitate
autophagic clearance through interaction with p62 [34]. Ubiquitin
may also be involved in coating of the damaged proteins, which
should preclude further growth of the aggregate and prevent
potentially toxic interactions [35].
MDBs as well as inclusions observed in tauopathies and poly-
glutamine diseases, but not synucleinopathies, harbour a frameshifted
form of ubiquitin termed UBB(+1) [36–39]. UBB(+1) arises as a
consequence of dinucleotide deletion during or after transcription and
is produced at similar levels in a variety of conditions [40]. It isicosis. Samples from trabecular hepatocellular carcinoma (a, b) and idiopathic copper
mically labelled with antibodies to keratins (c, d), p62 (b, f, g) and ubiquitin (e). MDBs as
s in e–g, appear also as red inclusions in a). Keratin antibodies strongly decorate MDBs
me IHBs contain occasional keratin granules suggesting that IHBmaterial (p62) provides
ic copper toxicosis sample contain both MDBs and IHBs, sometimes in close proximity,
Fig. 3.MDBs regularly stain with antibodies to ubiquitin, keratins and p62. Liver sections from a cirrhotic patient with alcoholic steatohepatitis (a, b), a patient with primary biliary
cirrhosis (c) and non-alcoholic steatohepatitis (d–f) were stained with antibodies to keratins 8 and 18 (a, b, d), ubiquitin (e) and p62 (c, f). MDBs are strongly labelled by all three
antibodies (e; arrows in a, arrowheads in d). Note that ballooned hepatocytes containing MDBs show greatly diminished or even absent cytoplasmic keratin immunostaining,
whereas normal-sized hepatocytes retain their keratin cytoskeleton (arrows in a, arrowheads in d).
Table 2
Selected murine models of human aggregate-forming diseases
Inclusion body Animal model Reference
NFT wt/mt Tau alone/with other proteins [24]
Lewy bodies wt/mt α-synuclein [24]
Lewy bodies Administration of rotenone, MPTP, MPP+ etc [22]
GCI wt α-synuclein [24]
MDBs Feeding with DDC/griseofulvin [7]
Htt aggregates Truncated/full-length form of mt Htt [23]
Rosenthal ﬁbers wt/mt GFAP [13]
GCI, Glial cytoplasmic inclusions; GFAP, Glial ﬁbrillary acidic protein; htt, huntingtin;
MDBs, Mallory–Denk-bodies; mt, mutant; NFT, neuroﬁbrillary tangles; wt, wild type.
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accumulation can cause proteasome inhibition both in cell culture and
in vivo [41,42]. Therefore, elevated UBB(+1) levels may both signalize
impaired proteasome function and accelerate disease progression
through additional proteasome impairment [40].
Ubiquitin-like protein NEDD8 has also been detected in numerous
aggregates including MDBs [43,44]. Although its function is largely
unknown, it can promote degradation of its substrates via adaptor
proteins NUB1 and NUB1 ligand and this process is involved in
clearance of Lewy body-like inclusions [45].
P62 is another constituent of a variety of aggregates [4,46]. It
represents an ubiquitin-binding protein which may facilitate both
proteasomal and autophagic degradation [47–49]. The potential
involvement of proteasomal system in inclusion degradation is further
highlighted by frequent co-localization of protein aggregates with
proteasomal subunits [7,50,51].
3. Posttranslational modiﬁcations of proteins affect aggregate
formation
The similarities between inclusion bodies extend to protein
modiﬁcations. Aggregated species are typically misfolded and highly
insoluble. In addition, they are often hyperphosphorylated, transami-
dated and partially degraded/proteolytically processed. Interestingly,these posttranslational modiﬁcations may have analogous impact on
the aggregation process independent of the particular protein
involved. For example, protein aggregates usually exhibit altered
conformation with increased β-sheet formation as it has been shown
for MDBs [52], inclusions seen in Alzheimer's, Parkinson, Huntington's
disease and many others disorders [5]. The uniformity of these
structures is highlighted by antibodies cross-reacting with oligomeric
species independent of their constituent proteins [53]. Furthermore,
diverse aggregates can also be stained by agents with afﬁnity for
β-sheet protein conformation such as thioﬂavin or congo red [7,54].
Among them, congo red does not only stain aggregates, but also
769P. Strnad et al. / Biochimica et Biophysica Acta 1782 (2008) 764–774interferes with the process of protein misfolding and aggregation and
shows some promise for treatment of inclusion-forming diseases [55].
Apart from phosphorylation (see below), oxidative modiﬁcations
might be involved in protein precipitation. They cause conformational
changes and exposure of hydrophobic domains, which would
otherwise be hidden within the properly folded polypeptide. The
exposed residues then interact with each other and other cellular
components thereby resulting in protein aggregation [56]. For
example, nitration and oxidation ofα-synuclein generates crosslinked
oligomers [57,58] and iron together with peroxide promotes NACP/
α-synuclein aggregation in vitro [59]. Several antioxidant compounds
were also demonstrated to counteract inclusion formation in different
settings. For example, S-adenosylmethionine and mito Q attenuated
MDB formation in DDC-primed mice ([60]; Zatloukal et al., unpub-
lished data), and antioxidant compounds show potent anti-α-
synuclein-ﬁbrillogenic properties in vitro [61]. However, such drugs
exhibit a variety of different effects and the attenuation of aggregate
formation may not be always related to decrease in oxidative stress.
For example, lack of MDB formation after S-adenosylmethionine
administrationwas explained as a result of interactionwith epigenetic
histone modiﬁcations rather than being a result of antioxidant
properties [60].
The aggregated proteins are often hyperphosphorylated and
protein phosphorylation may promote aggregate formation. To that
end, MDBs consist of heavily hyperphosphorylated keratins [62] and
ablation of keratin 8 S73 phosphorylation site in mice results in
diminished MDB formation, whereas alteration of keratin 18 phos-
phorylation does not have an obvious effect ([63]; Harada et al.,
unpublished results). Furthermore, keratin 8 S73 is phosphorylated by
p38 kinase and a p38 inhibitor prevents MDB formation in DDC-
primed hepatocytes [64,65]. Similarly to keratins, α-synuclein is
phosphorylated at serine residues with Ser 129 being the major
phosphorylation site [66]. The extent of phosphorylation is consider-
ably higher in insoluble synuclein when compared to the normal
protein [66] and the abolition of the Ser 129 phosphorylation site
results in decreased inclusion formation [67]. Tau is another
established phosphoprotein and its abnormal phosphorylation pro-
motes dissociation from microtubules, formation of neuroﬁbrillary
tangles and neurodegeneration [68]. GSK3β, CDK5 and ERK2 are the
most relevant kinases involved in this process and their speciﬁc
inhibitors are currently evaluated as potential treatments in tau-
related neurodegenerative diseases [68]. The beneﬁcial effect of
GSK3β and CDK5 inhibitors may extend to inclusion body myositis,
which contains hyperphosphorylated tau forming paired helical
ﬁlaments [69]. Moreover, protein aggregation might be stimulated
by stress-responsive kinase MEKK1 in polyglutamine disorders [70].
Finally, JNK kinase contributes to GFAP accumulation and expression
of dominant negative JNK restores GFAP solubility in a cellular model
of Alexander's disease [71].
Protein crosslinking by transglutaminases (TG) was observed in
various inclusion bodies. It represents a largely irreversible protein
modiﬁcation, which results in protein oligomerization and was
implicated in aggregate formation [72]. For example, keratin 8 within
MDBs is crosslinked by TG2 and preventing this crosslinking might be
responsible for greatly reduced MDB formation observed in TG2-
knockout mice [73,74]. Enhanced protein crosslinking was detected in
multiple other aggregate-forming disorders such as inclusion body
myositis [75], Alzheimer [76], Parkinson [77] or Huntington's disease
[78]. Crosslinking might be directly involved in synuclein aggregation
or aggregates seen in Huntington's disease [77,79]. However, protein
crosslinking does not always predispose to inclusion body formation
as seen after crossing Huntington's disease (HD) R6/1 transgenic mice
with TG2-knockout mice, which even potentiated inclusion body
formation [80].
Aggregated proteins are often partially degraded or result from
regulated proteolytic processing. The former is true for keratins inMDBs [7,81], the latter for amyloid β in inclusion body myositis and
Alzheimer's disease [69,82] and proteins causing several polygluta-
mine disorders [83]. In the case of amyloid β, huntingtin and ataxin 3,
partial proteolysis can promote aggregation [82,83]. Accordingly,
inhibitors of responsible proteases may become interesting drug
targets. For example, β-secretase inhibitors are currently under
development and may prevent formation of amyloidogenic Aβ42
fragment [84].
4. Protein overexpression or disproportional production
accelerates inclusion formation
Both increased protein expression and/or abnormal ratio between
different protein species may predispose to formation of inclusion
bodies and/or extracellular protein plaques. In support of the former
hypothesis, individuals with trisomy 21, who have an extra copy of
amyloid β gene, develop the characteristic Alzheimer's disease
pathology at early age [82]. Similarly, a triplication of α-synuclein
locus causes early onset familiar Parkinson disease [85]. In transgenic
mice, Rosenthal ﬁber formation can be introduced by GFAP over-
expression [13]. However, the ratio between different protein
isoforms seems also to be important. For example, α-synuclein
exhibits three different isoforms generated through alternative
splicing and patients displaying dementia with Lewy bodies have
up-regulated expression of α-synuclein 112 and down-regulated
expression of α-synuclein 126 isoform [66]. Similarly, patients with
sporadic Alzheimer's disease exhibit a shift between different
amyloid β peptides, rather than amyloid-β precursor protein over-
expression [82]. Altered ratio between different neuroﬁlament
protein isoforms might be involved in aggregate formation in
amyotrophic lateral sclerosis [86]. Improper stoichiometric balance
between aggregate constituents rather than protein overexpression
likely precipitates murine MDB formation. In support of that, K8
overexpressing or K18-null mice, who have increased K8/K18 ratio,
produce inclusion bodies more rapidly, whereas mice overexpressing
both keratins 8 and 18 do not [7,87].
5. Chaperones attenuate aggregate formation
Since protein misfolding may result in inclusion formation [6],
chaperones facilitating protein folding and repair or degradation of
damaged proteins can protect from aggregation. Several studies
support this hypothesis [70]. For example, overexpression of inducible
Hsp70 or a concerted induction of several chaperones in HSF1
transgenes attenuated polyglutamine inclusion formation [88–90].
Accordingly, inclusion body formationwould indicate either impaired
or insufﬁcient chaperone function. Indeed, MDB formation after
chronic DDC intoxication is accompanied by decreased levels of
inducible Hsp70 and GRP75, persistent chaperone modiﬁcations and
compromised chaperone function [91]. This hypothesis may extend to
other aggregate-forming disorders, since mouse models of Hunting-
ton's disease and amyotrophic lateral sclerosis display reduced
chaperone levels as well [92,93].
6. Proteasomal and autophagic degradation are involved in
disposal of aggregation-prone proteins
To avoid the accumulation of damaged proteins, cells developed
two major degradative pathways, the UPS and autophagy. The
putative role of the UPS in preventing inclusion body formations is
based on three fundamental observations. The aggregated proteins are
heavily ubiquitinylated, i.e. marked for proteasomal degradation,
several inclusion bodies (including MDBs) contain proteasome
subunits and proteasome inhibition induces aggregate formation in
different models [7,50,51,94–96]. Despite such compelling evidence,
the relationship between UPS and inclusion formation is still not
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involved in complex aggregate pathogenesis. This is best evidenced in
the case of Parkinson disease, where UPS participates in clearance of
α-synuclein but other routes are also employed [97]. Support for the
relevance of UPS in Parkinson disease also comes from genetic studies,
sincemutations in ubiquitin ligase named parkin and deubiquitylating
enzyme UCHL1 are found in patients with familiar Parkinson disease
[98,99]. However, parkin represents a multifaceted enzyme and not all
its functions are related to UPS degradation [99]. Similarly, injection of
proteasome inhibitors into rodents was shown to cause parkinsonian
features [96], but several labs failed to replicate these ﬁndings [99]. In
the liver, proteasome inhibitors induced MDB formation in DDC-
primed mice as well as transgenic animals overexpressing keratin 8
[95,100].
While the function of UPS to degrade damaged proteins is clearly
established, it may not be able to provide sufﬁcient protein
degradation in certain conditions. For example, a recent study showed
that an accumulation of lysine 48-linked polyubiquitin chains, i.e.
chains marking proteins for UPS degradation, is a common feature in
patients and animal models of Huntington's disease [101]. Several
reasons may account for the inability of UPS to degrade and recycle
proteins. For example, cellular proteasomes might be depleted [102]
or the proteasome activity decreased as it happens during aging and
oxidative stress [103,104]. UPS might be unable to degrade larger
oligomers possibly because such substrates do not pass through its
narrow entry pore [105]. Some studies even claim that UPS becomes
inhibited by aggregates, although this theory remains controversial
and is not yet conﬁrmed in vivo [50]. UPS was also shown to be
inhibited by accumulation of frameshifted UBB(+1) [41,42]. Alterna-
tively, some protein species might accumulate because they are
difﬁcult to digest [106,107]. The inability to degrade a subset of
proteins was recently observed in MDB-forming mice, which show
accumulation of ubiquitinylated proteins in the insoluble, but not the
soluble pool. The accumulation of insoluble ubiquitinylated proteins
coincides with formation of high molecular weight species, thereby
suggesting that these large structures might be indigestible by the UPS
[74].
While UPS represents the preferred way to dispose short-lived
proteins under normal conditions, autophagy steps in when UPS is
overwhelmed, inhibited or unable to digest certain protein species
[108,109]. For example, UPS inhibition or the presence of certain
aggregates augments autophagic degradation [110,111]. Autophagy
may degrade substrates which are difﬁcult to be degraded by UPS,
such as proteins with expanded polyglutamine repeats [112,113].
Therefore, stimulating autophagy represents a promising target in
aggregate-forming diseases, which can decrease the amount of
inclusions and prevent cell death [108,113]. Similarly to polyglutamine
diseases, autophagy is up-regulated during MDB formation in mice
and further stimulation can prevent MDB formation in vivo [114]. A
potential advantage of autophagic vs. UPS degradation is the fact that
autophagymay also degrade smaller aggregates [97]. However, similar
to the UPS, autophagic activity decreases during aging and may be
impaired in certain disease conditions [109,115].
7. P62 promotes protein sequestration and facilitates proteins
degradation
P62 is one of the most abundant inclusion body constituents and
was frequently implicated in aggregate formation [4,46,116–120]. It
represents on the one hand a linker molecule involved in NFκB as well
as other signaling pathways, and on the other hand, a ubiquitin-
binding protein which interacts via its UBA-domain with species
ubiquitinylated via lysine 63. Although this modiﬁcation is not
typically associated with protein degradation, p62 has been shown
to shuttle substrates to both proteasomal and autophagic machineries
[47–49,121,122]. Under normal conditions, the action of p62 seems tobe protective, since it prevents accumulation of toxic, aggregation-
prone proteins [49,123]. However, when autophagy is inhibited, it
favours aggregate formation and is associated with increased
oxidative stress, probably through stabilization of toxic protein
intermediates [118].
Cell culture experiments showed that p62 is involved in MDB
formation and that its ubiquitin-binding site is a necessary prerequi-
site for this process [18]. For example, the combined transfection of
p62, keratin 8 or 18 and ubiquitin resulted in aggregates with typical
MDB ultrastructure; such inclusions, however, did not formwhen only
K8, K18 and ubiquitin were transfected alone or in combination [18].
Furthermore, in DDC-primed hepatocytes, p62 inhibition attenuated,
whereas p62 overexpression enhanced MDB formation [124]. In vivo
studies are needed to conﬁrm the cell culture data.
8. Aggresomes and sequestosomes are terms describing the
process of aggregate formation
Inclusion body formation in vivo does not simply result from
coalescence of misfolded proteins. For example, two aggregation-
prone proteins expressed in the same cell do not necessary co-
aggregate together, but can form independent entities [125]. Cell
culture experiments suggested that small protein aggregates form in
the cell periphery ﬁrst and are then transported viamicrotubule tracks
to a central disposal place in the vicinity of the centrosome
[14,126,127]. The structure resulting from this “aggregation of
aggregates” is termed aggresome. It co-localizes with centrosome
markers such as pericentrin or γ-tubulin and is surrounded by
intermediate ﬁlaments displaying a cage- or ring-like arrangement
[14,126–128]. In addition to sequestering potentially toxic proteins,
aggresomes are thought to aid protein degradation by bringing them
to a place rich in chaperones and proteasome subunits. Aggresome
formation also likely facilitates autophagic degradation [129–131]. On
the other hand, aggresome formation may lead to disorganization of
microtubule arrays and disruption of the Golgi apparatus [132].
Among naturally occurring inclusions, Lewy bodies seem to
resemble aggresomes [128], since they co-localize with centrosome
markers and contain radiating intermediate ﬁlaments. The sequential
process of aggresome formation is also replicated in cell culture and
supported by the presence of small aggregates in neuronal processes
(termed as Lewy neurites), which may represent the primary
aggregates seen in aggresome formation [133,134]. On the other
hand, neither mutant tau in neuroﬁbrillary tangles nor mutant
huntingtin seem to form aggresomes [5]. Similarly, MDBs do not co-
localize with γ-tubulin, even though their formation in primary
hepatocytes is inhibited by antimicrotubule agents [87,135].
The term “sequestosome” was proposed by Shin to designate a
cytoplasmic storage compartment in the cell, not delimited by
membranes, containing p62 in combination with polyubiquitinylated
proteins [136]. Similarly, to aggresomes, the author suggested that
proteins stored in sequestosomes are upon proper signals released for
proteasomal (or autophagic) degradation. This was later conﬁrmed by
several studies highlighting the importance of p62 for both protea-
somal and autophagic degradation [48,49,137]. Since p62 is a common
constituent of multiple human inclusion bodies and since these
aggregates are usually ubiquitinylated (Table 1; [4,46]), the term
“sequestosome” is more suitable than “aggresome” to describe the
aggregates seen in multiple human disorders [138]. Importantly, both
terms are not exclusive in that some inclusions comply with both
deﬁnitions [137].
9. Oligomers rather than macroscopic aggregates seem to be the
toxic species
One important aim of our review is to point out that the protein
aggregation process follows the same rules independent of the tissue
771P. Strnad et al. / Biochimica et Biophysica Acta 1782 (2008) 764–774involved. Therefore, insights into MDB pathogenesis may enhance
our understanding of aggregate formation in multiple other disorders
and – vice versa –MDB research can greatly beneﬁt from ﬁndings
obtained when studying non-hepatic aggregates. As an example,
ﬁndings from non-hepatic aggregates shaped our view of MDB
formation process and will likely be helpful in deciphering the MDB
signiﬁcance in general.
To that end, formation of large protein inclusions was long thought
to be detrimental in multiple ways such as interfering with cellular
transport processes (e.g. shown with microtubule-dependent trans-
port in neurons), depriving the cell of vital components trapped in the
aggregates or inhibiting the protein degradation machinery [104,139–
143]. However, recent studies argue that large aggregates are
biologically inert or even protective. For example, the presence of
MDBs per se does not seem to compromise hepatocyte viability in vivo
and of transfected tissue culture cells in vitro [4,18]. In Parkinson and
Huntington's disease, there is little correlation between the presence
of Lewy bodies/huntingtin aggregates and the extent of cell death
[144,145]. Recently, Arrasate et al. [146] performed long-term
monitoring of cells using an automated microscope and showed that
the ones forming aggregates are less likely to die. Accordingly, a
chemical compound, which promotes inclusion formation, lessened
the toxicity of aggregation-prone proteins in cellular models of
Huntington's and Parkinson disease [147].
This led to the current understanding that small oligomers/
protoﬁbrils rather than huge aggregates are the toxic species. This is
best evidenced in Alzheimer's disease. For example, injection of Aβ
into brain of rats resulted in toxic effects, which could be alleviated by
co-injection of an oligomer-speciﬁc antibody [148]. Accordingly, both
pathogenic α-synuclein mutations and the Aβ 42 form protoﬁbrils
more rapidly than non-pathogenic proteins [149,150]. In addition,
dopamine can build adducts with α-synuclein, thereby stabilizing
their oligomeric structure [151]. The latter observation may explain
the selective dopaminergic neurotoxicity of α-synuclein in Parkinson
disease [151]. The toxicity of oligomeric species may be due to
formation of pore-like structures, which can be formed by Aβ, α-
synuclein as well as polyglutamine peptides [152,153]. In addition,
non-ﬁbrillar α-synuclein inhibits proteasomal activity and oligomeric
species might be generating reactive oxygen species through interac-
tions with redox-active metal ions [154,155].
10. Concluding remarks
Our review summarizes the recent advances in our under-
standing of MDB pathogenesis and shows how they relate to
observations made in other aggregates. MDBs are hepatocellular
inclusions while the most widely studied aggregates are typically
found in neurodegenerative disorders. Despite the inherent differ-
ences between the tissues involved, the inclusions share common
molecular constituents, analogue posttranslational modiﬁcations,
alterations in protein expression and the involvement of protein
repair and degradation machineries. Therefore, aggregates seen in
different human disorders should be considered an extended family,
which has a common foundation, but contains members with
distinct personalities. Furthermore, MDBs represent an interesting
tool to test the effect of pharmaceutical interventions on aggregate
formation. This might be especially useful to evaluate the role of UPS
in inclusion pathogenesis, as for example the proteasome inhibitor
bortezomib is already FDA-approved for treatment of multiple
myeloma.
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